Breast Biopsy Devices Market Size & Growth Forecast 2027–2036, By Segments (Technique, End-use, Product), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growoth Outlook
Breast Biopsy Devices Market size stood at USD 2.25 Billion in 2026 and is predicted to grow at 7.21% CAGR from 2027 to 2036, exceeding USD 4.51 Billion by 2036. The industry revenue for 2027 is assessed at USD 2.39 Billion.
Get more details on this report
Request Free Sample ReportBreast Biopsy Devices Market Intelligence Snapshot
Regional Market Dynamics
- North America led in 2026 due to developed screening programs, advanced diagnostic imaging, specialized breast-care centers, and established pathways for image-guided biopsy procedures.
- Asia Pacific benefits from expanding screening initiatives, improving diagnostic infrastructure, rising healthcare expenditure, and increasing adoption of minimally invasive biopsy technologies.
Segment Momentum
- Image guided biopsy accounted for 69.31% of the market in 2026 due to its ability to accurately localize suspicious lesions, improve procedural precision, and support minimally invasive breast biopsy procedures.
- Ambulatory surgical centers are the fastest-growing end-use segment as demand rises for minimally invasive outpatient procedures, shorter recovery times, cost-efficient care, and improved procedural workflows.
Market Expansion Drivers
- Rising breast cancer incidence driving demand for early diagnostic biopsy procedures
- Technological advancements in minimally invasive biopsy devices improving diagnostic accuracy
- Favorable reimbursement policies increasing accessibility of breast cancer screening procedures
Leading Market Participants
- Top companies in the breast biopsy devices market include Stryker Corporation (United States), Boston Scientific Corporation (United States), Hologic, Inc. (United States), Becton, Dickinson and Company (United States), Medtronic plc (Ireland), Olympus Corporation (Japan), Cook Group Incorporated (United States), Argon Medical Devices, Inc. (United States), FUJIFILM Holdings Corporation (Japan)
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 2.25 Billion
- 2027 Estimated Market Size: USD 2.39 Billion
- Projected Market Size: USD 4.51 Billion by 2036
- Growth Forecast: 7.21% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Image Guided Biopsy (Technique) | Hospitals (End-use) | Needle Based Breast Biopsy Guns (Product)
- Emerging Opportunity Segment: Liquid Biopsy (Technique) | Ambulatory Surgical Centers (End-use) | Breast Biopsy Guidance Systems (Product)
Market Growth Drivers and Industry Trends
Rising breast cancer incidence driving demand for early diagnostic biopsy procedures
The increasing incidence of breast cancer is reinforcing the importance of timely diagnosis, prompting healthcare providers to expand the use of biopsy procedures for accurate tissue evaluation. The breast biopsy devices market is benefiting from growing emphasis on early disease detection, as clinicians rely on biopsy technologies to confirm suspicious findings identified through screening and diagnostic imaging. Rising awareness of the clinical benefits associated with earlier diagnosis is also encouraging greater participation in breast health programs, increasing the demand for reliable and efficient biopsy solutions across hospitals, diagnostic centers, and specialized breast care clinics.
Technological advancements in minimally invasive biopsy devices improving diagnostic accuracy
Continuous innovation in biopsy technologies is improving procedural precision while reducing patient discomfort and recovery time. This trend will propel the breast biopsy devices market as minimally invasive systems enable clinicians to obtain high-quality tissue samples with greater accuracy and reduced procedural complexity. Enhanced imaging compatibility, refined needle designs, and improved specimen collection capabilities are supporting more confident diagnoses while encouraging wider clinical adoption across diverse breast imaging and interventional settings.
Favorable reimbursement policies increasing accessibility of breast cancer screening procedures
Supportive reimbursement frameworks are making breast cancer screening and diagnostic services more accessible to broader patient populations by reducing financial barriers to care. The breast biopsy devices market is expanding as improved coverage encourages greater utilization of diagnostic pathways that include biopsy procedures when abnormal findings require further evaluation. Healthcare providers are also strengthening screening initiatives by integrating accessible diagnostic services that facilitate timely clinical decision-making and appropriate treatment planning.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Rising breast cancer incidence driving demand for early diagnostic biopsy procedures | 2% | High | North America, Europe | High | Near Term |
| Technological advancements in minimally invasive biopsy devices improving diagnostic accuracy | 1.8% | High | North America, Asia Pacific | High | Mid Term |
| Favorable reimbursement policies increasing accessibility of breast cancer screening procedures | 1.6% | High | Europe, North America | High | Mid Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America (Largest Region)
In the breast biopsy devices market, North America held the largest position in 2026, reflecting well-developed breast cancer screening programs, widespread access to advanced diagnostic imaging, and strong clinical emphasis on early detection. The availability of specialized breast-care centers and established diagnostic pathways supports the use of image-guided biopsy procedures when suspicious lesions are identified. Increasing awareness of breast cancer screening and continued improvements in minimally invasive biopsy technologies are also encouraging the adoption of devices that provide accurate tissue sampling while reducing patient discomfort.
Asia Pacific (Fastest-Growing Region)
Asia Pacific is expected to register the fastest growth, driven by increasing awareness of breast cancer, expanding screening initiatives, and improving diagnostic infrastructure. Growing healthcare expenditure and the development of specialized oncology and imaging centers are making breast biopsy procedures more accessible across emerging markets. In addition, rising demand for minimally invasive diagnostic techniques and greater emphasis on detecting breast abnormalities at earlier stages are encouraging healthcare providers to adopt advanced biopsy systems.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
United States 🇺🇸
Image-Guided DiagnosticsThe U.S. prioritizes advanced breast biopsy devices that integrate with imaging systems to improve diagnostic accuracy and procedural efficiency. Healthcare providers continue expanding minimally invasive biopsy capabilities within breast cancer screening programs.
Germany 🇩🇪
Minimally Invasive ProceduresGermany supports breast biopsy technologies that reduce procedural burden while maintaining high diagnostic confidence. German healthcare facilities continue modernizing biopsy workflows through image-guided and precision sampling devices.
Japan 🇯🇵
Early Detection SupportJapan aligns breast biopsy device adoption with established breast cancer screening initiatives and early diagnostic practices. Japanese healthcare providers emphasize precise tissue sampling technologies that enhance clinical confidence and patient care.
South Korea 🇰🇷
Advanced Imaging CompatibilitySouth Korea encourages breast biopsy devices designed for compatibility with modern imaging platforms and minimally invasive procedures. Healthcare providers seek efficient diagnostic tools that support streamlined breast cancer evaluation pathways.
France 🇫🇷
Screening Program AlignmentFrance integrates breast biopsy devices into organized breast cancer screening and diagnostic services to improve clinical efficiency. French hospitals prioritize reliable biopsy technologies that support accurate tissue collection with reduced patient discomfort.
Italy 🇮🇹
Clinical Workflow EfficiencyItaly is strengthening access to breast biopsy devices that simplify diagnostic procedures across hospitals and specialty clinics. Italian healthcare providers increasingly value systems that improve workflow efficiency while supporting accurate breast lesion assessment.
Segment Leadership and Growth Trends
Breast Biopsy Devices Market Share (%), Technique, 2025
Go beyond the chart, access full insights & data tables
Request Free Sample ReportTechnique Segment Analysis: Image Guided Biopsy (Largest Segment) vs Liquid Biopsy (Fastest-Growing Segment)
Holding the largest share of the breast biopsy devices market, the image guided biopsy segment captured 69.31% in 2026. The segment benefits from its ability to accurately localize suspicious breast lesions while improving procedural precision and reducing unnecessary tissue removal. Broad clinical acceptance, integration with advanced imaging technologies, and increasing demand for minimally invasive diagnostic procedures continue to reinforce its leading position.
The liquid biopsy segment is expected to witness the fastest growth over the forecast period as interest in less invasive diagnostic approaches continues to increase. Advancements in biomarker detection technologies and growing focus on personalized cancer management are encouraging broader research and clinical adoption. The potential to support disease monitoring with reduced patient discomfort is expected to further strengthen the expansion of this segment.
End-use Segment Analysis: Hospitals (Largest Segment) vs Ambulatory Surgical Centers (Fastest-Growing Segment)
The hospitals segment accounted for the largest share of 58.66% in 2026. Hospitals remain the primary setting for breast biopsy procedures because they offer comprehensive diagnostic imaging, experienced multidisciplinary teams, and access to advanced pathology services. Their ability to manage complex cases and provide integrated cancer care continues to support sustained demand for breast biopsy devices.
The ambulatory surgical centers segment is anticipated to experience the fastest growth in the breast biopsy devices market. Increasing preference for minimally invasive outpatient procedures, shorter recovery times, and cost-efficient healthcare delivery is driving patient migration toward these facilities. Continued improvements in procedural capabilities and streamlined clinical workflows are also contributing to expanding utilization of ambulatory surgical centers.
Product Segment Analysis: Needle Based Breast Biopsy Guns (Largest Segment) vs Breast Biopsy Guidance Systems (Fastest-Growing Segment)
The needle based breast biopsy guns segment held the largest market share of 34.13% in 2026. Its leadership is supported by widespread clinical use for obtaining accurate tissue samples with minimally invasive techniques, making it a preferred choice across routine breast biopsy procedures. Consistent demand for reliable sampling devices and ongoing improvements in ergonomic design and procedural efficiency continue to reinforce the segment's market position.
In the breast biopsy devices market, the breast biopsy guidance systems segment is expected to record the fastest growth during the forecast period. Increasing adoption of image-assisted procedures, growing emphasis on diagnostic precision, and continuous technological advancements are driving demand for guidance systems. Their ability to improve lesion targeting and enhance procedural confidence is expected to accelerate adoption across modern breast imaging and diagnostic centers.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Technique | Image Guided Biopsy, Liquid Biopsy | Image Guided Biopsy | Liquid Biopsy |
| End-use | Hospitals, Ambulatory Surgical Centers, Others | Hospitals | Ambulatory Surgical Centers |
| Product | Breast Biopsy Guidance Systems, Needle Based Breast Biopsy Guns, Breast Biopsy Needles, Breast Biopsy Forceps, Others | Needle Based Breast Biopsy Guns | Breast Biopsy Guidance Systems |
Competitive Landscape and Market Positioning
Key companies in the breast biopsy devices market:
- Stryker Corporation (United States)
- Boston Scientific Corporation (United States)
- Hologic, Inc. (United States)
- Becton Dickinson and Company (United States)
- Medtronic plc (Ireland)
- Olympus Corporation (Japan)
- Cook Group Incorporated (United States)
- Argon Medical Devices, Inc. (United States)
- FUJIFILM Holdings Corporation (Japan)
Product differentiation is increasingly centered on procedural precision and workflow integration rather than the standalone performance of biopsy instruments. Manufacturers are directing development efforts toward systems that improve targeting accuracy, reduce procedural complexity, and integrate more effectively with advanced breast imaging platforms used across diagnostic settings. As healthcare providers seek to standardize minimally invasive procedures while improving patient experience, suppliers capable of offering interoperable technologies, clinical training, and dependable service support are strengthening their competitive position. This shift places greater pressure on participants with narrower portfolios, encouraging them to emphasize specialized procedural expertise or highly adaptable device configurations that address diverse clinical preferences.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| No companies available. | |||||||
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| GE HealthCare | Apr-25 | GE HealthCare unveiled the Serena Bright contrast-guided biopsy system at the Society of Breast Imaging Symposium. The technology enhances lesion visualization during contrast-enhanced mammography, representing a commercially significant advancement in diagnostic precision for clinical procedures. |
| Mammotome | Feb-25 | Mammotome entered into an exclusive distribution agreement with Sirius Medical covering the United States and Germany. The partnership integrates Mammotome's established breast care expertise with Sirius Medical's advanced surgical marker navigation technology to strengthen market positioning. |
| Hologic | Jan-25 | Hologic completed the acquisition of Gynesonics, expanding its gynecological surgical portfolio. This strategic transaction enhances the company's footprint in women's health by integrating advanced, minimally invasive clinical solutions into its core commercial offerings. |
| Mammotome | Aug-22 | Mammotome launched the Mammotome Revolve EX, a vacuum-assisted biopsy system engineered for the efficient excision of benign breast lesions. The system delivers double the operational speed of traditional alternatives, significantly expanding the company's procedural portfolio and competitive edge. |
Explore This Report
Click a section of the wheel — or its numbered marker — to preview the custom segmentation, custom table of contents, or related reports available for this market.
Breast Biopsy Devices Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| No segment data available. | |
Breast Biopsy Devices Market — report.custom
| Custom Chapter | Custom Details | ||
|---|---|---|---|
| No custom TOC data available. | |||
Need a different cut of the data?
Request Custom ResearchHow large is the breast biopsy devices market?
How will the breast biopsy devices industry grow in terms of size and CAGR by 2035?
How are minimally invasive biopsy technologies reshaping the breast biopsy devices market?
Why are breast biopsy procedures seeing greater clinical adoption?
Why is image guided biopsy the leading technique in the breast biopsy devices market?
Which end-use segment is growing the fastest in the breast biopsy devices market?
What supports North America's leadership in the breast biopsy devices market?
Why is Asia Pacific expected to grow fastest in the breast biopsy devices market?
Who holds a significant market share in the breast biopsy devices landscape?
Our Clients
"The reports offered a comprehensive view of the Food and Beverage landscape, covering market trends, consumer behavior, and competitive dynamics."
"Our experience in acquiring market research reports has been outstanding — the depth of analysis and actionable insights have proven invaluable."
"Fundamental Business Insights demonstrated a keen understanding of our business needs, delivering reports tailored to our specific objectives."
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source Category | Research Sources | Purpose |
|---|---|---|
| Government Publications | Government agencies, statistical departments, regulatory bodies | Industry statistics, regulatory insights, and policy analysis |
| Company Disclosures | Annual reports, investor presentations, financial filings | Company performance, business strategy, and market positioning |
| Trade Associations | Industry associations and professional organizations | Industry developments, standards, and market perspectives |
| Technical Literature | Research papers, technical publications, academic journals | Technology developments and technical validation |
| Patent Analysis | Patent databases and intellectual property publications | Innovation trends, technology activity, and competitive research |
| Industry Databases | Established research databases and market intelligence resources | Market benchmarking, historical data, and industry analysis |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization